Exclusive

Publication

Byline

Location

Nutritionist outlines who may benefit from electrolyte drinks and cautions against daily commercial use

India, Nov. 3 -- Celebrity nutritionist Nikita Garg, founder of Entech Wellness, said in an interview with HT Lifestyle that electrolyte drinks are not necessary for everyone and that people should un... Read More


Singapore Clinical Trial: A Phase II, Open-label Platform Study of Osimertinib in Combination with Anti-cancer Agents in Participants With EGFR-mutated Metastatic Non-small Cell Lung Cancer Whose Disease Has Progressed on Prior Osimertinib and Chemotherapy Combination Treatment (GROVE)

Singapore, Nov. 3 -- The Health Sciences Authority received information related to the study titled 'A Phase II, Open-label Platform Study of Osimertinib in Combination with Anti-cancer Agents in Part... Read More


Singapore Clinical Trial: A Phase III, Randomized, Double-Blind, Placebo-Controlled, Trial To Evaluate The Efficacy And Safety Of Enicepatide In Participants With Overweight Or Obesity And Heart Failure With Reduced Ejection Fraction

Singapore, Nov. 3 -- The Health Sciences Authority received information related to the study titled 'A Phase III, Randomized, Double-Blind, Placebo-Controlled, Trial To Evaluate The Efficacy And Safet... Read More


Singapore Clinical Trial: A two-part, First-In-Human, phase I, open-label, ascending dose study to assess safety and tolerability of DKB903 in participants with Rheumatoid Arthritis (RA) and participants with Systemic Lupus Erythematosus (SLE).

Singapore, Nov. 3 -- The Health Sciences Authority received information related to the study titled 'A two-part, First-In-Human, phase I, open-label, ascending dose study to assess safety and tolerabi... Read More


Singapore Clinical Trial: A Phase 2, Randomized, Open-Label Dose Optimization and Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of Tersolisib (LY4064809) Combined with a CDK4/6 Inhibitor and Endocrine Therapy in Adults with HR+, HER2- Advanced Breast Cancer with a PIK3CA Mutation Who Received No Prior Treatment for Advanced Breast Cancer (PIKALO-2)

Singapore, Nov. 3 -- The Health Sciences Authority received information related to the study titled 'A Phase 2, Randomized, Open-Label Dose Optimization and Phase 3, Randomized, Double-Blind, Placebo-... Read More


Singapore Clinical Trial: A Phase 1 Open-Label Study to Determine the Effect of Injection Site on the Relative Bioavailability of a Single Subcutaneous Dose of LY3841136 and to Evaluate the Pharmacokinetics of a Single Intravenous Dose of LY3841136 in Healthy Participants.

Singapore, Nov. 3 -- The Health Sciences Authority received information related to the study titled 'A Phase 1 Open-Label Study to Determine the Effect of Injection Site on the Relative Bioavailabilit... Read More


Singapore Clinical Trial: Efficacy of Yang Shen Dan in Mild to Moderate Alzheimer’s Disease: Randomised controlled study

Singapore, Nov. 3 -- The Health Sciences Authority received information related to the study titled 'Efficacy of Yang Shen Dan in Mild to Moderate Alzheimer’s Disease: Randomised controlled study'. Th... Read More


Singapore Clinical Trial: A First-in-Human, Open-Label, Multi-Center Phase I/II Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Antitumor Activity of ALK201 for Injection in Adult Participants with Advanced Solid Tumors

Singapore, Nov. 3 -- The Health Sciences Authority received information related to the study titled 'A First-in-Human, Open-Label, Multi-Center Phase I/II Clinical Study to Evaluate the Safety, Tolera... Read More


Singapore Clinical Trial: A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Ensifentrine (MK-5884) Versus Placebo for the Prevention of COPD Exacerbations in Adults with a History of Moderate or Severe Exacerbations While Receiving Standard of Care (ENHANCE-3)

Singapore, Nov. 3 -- The Health Sciences Authority received information related to the study titled 'A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety o... Read More


Singapore Clinical Trial: An open-label, roll-over study evaluating the long-term safety and efficacy of an oral dose of verducatib q.d. in patients with bronchiectasis (AIRTIVITY®-ON)

Singapore, Nov. 3 -- The Health Sciences Authority received information related to the study titled 'An open-label, roll-over study evaluating the long-term safety and efficacy of an oral dose of verd... Read More